BPC-157 gummies trial to assess inflammation, physical performance, and recovery in active adults

For years, the peptide Body Protection Compound 157 (BPC-157) has been explored for its regenerative potential, particularly in treating musculoskeletal injuries like partial muscle or tendon tears. Preclinical studies consistently show its ability to promote healing in fractures, tendon ruptures, and ligament tears by fostering mucosal integrity and homeostasis. However, human data, especially concerning oral or intravenous administration, remains scarce. This lack of robust clinical evidence creates a significant gap, hindering its widespread adoption and understanding in human applications, particularly for physically active individuals seeking enhanced recovery and reduced inflammation.

This IRB-approved clinical trial will enroll 40 physically active adults to evaluate the effects of Parlay Recover peptide gummies containing BPC-157. Participants will consume two gummies daily over an 8-week period. The primary objective is to measure changes in inflammatory biomarkers, specifically hs-CRP and IL-6, via blood testing at Baseline and Week 8. Secondary objectives include assessing self-reported perceptions of physical performance and recovery, encompassing aching, stiffness, function, and muscle/joint recovery, using questionnaires administered at Baseline, Week 2, Week 4, Week 6, and Week 8. This is a single-arm intervention study.